医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Camargo President to Present on the 505(b)(2) Drug Development Pathway at the 4th Chinese Pharmaceutical Industry Globalization Workshop

2012年10月24日 AM12:25
このエントリーをはてなブックマークに追加


 

CINCINNATI

An expert in the 505(b)(2) drug development process, Ken Phelps, Camargo Pharmaceutical Services founder, president and CEO, will be a keynote speaker at the 4th Chinese Pharmaceutical Industry Globalization Workshop, November 1 in Shanghai, China.

The workshop, hosted by Frontage Laboratories, provides key guidance to successfully conduct new and generic drug development processes and helps companies understand the U.S. Federal Drug Administration’s (FDA) regulatory requirements for successful pre-IND and IND submissions, 505(b)(2) drug development and orphan drug R&D submissions.

Phelps will speak alongside executive members from Frontage Laboratories, the FDA, the China Pharmaceutical Enterprises Association and Luye Pharma.

With more than three decades of experience, Phelps and his team attain two to five pre-IND meetings before the FDA per month. Working with companies around the globe in 26 countries, Camargo provides successful FDA approval of numerous products each year.

“We are pleased to have such a renowned expert present at our annual workshop,” said Song Li, Ph.D., Frontage founder, chairman and CEO. “Frontage and Camargo have successfully worked together over the years on several development programs like those to be discussed during this forum. Ken’s 505(b)(2) expertise has proven to be a great resource for us and our clients as we work to move new drugs into the U.S. marketplace.”

Camargo is an end-to-end drug development service provider that specializes in the 505(b)(2) process. The company serves as a solution for pharmaceutical and biotechnology companies around the world looking to enter the U.S. drug market with new or reformulated drugs in a fraction of the time and cost required by traditional paths.

About Camargo Pharmaceutical Services
Camargo Pharmaceutical Services is your full-service drug development partner specializing in the 505(b)(2) process. Before development even begins, we verify profit potential by working with your team to develop a comprehensive program and timeline complete with important milestones and cost objectives. We manage every facet of the plan throughout your development continuum, from feasibility assessments, formulation and testing the drug product, to conducting preclinical and clinical studies, to final submission. Connect with Camargo on LinkedIn, the President’s blog or visit www.camargopharma.com for more information.

CONTACT

For Camargo Pharmaceutical Services:
SCORR Marketing
Lea
Studer, 308-237-5567
lea@scorrmarketing.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Orthocell Granted European Tendon Regeneration Patent
  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China